{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:20:28Z","timestamp":1774416028746,"version":"3.50.1"},"reference-count":9,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.euf.2025.07.016","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T11:24:42Z","timestamp":1753701882000},"page":"34-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Future of Novel Antibody-drug Conjugates in Localized Urothelial Cancer"],"prefix":"10.1016","volume":"12","author":[{"given":"Mikolaj","family":"Filon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1233-1638","authenticated-orcid":false,"given":"Bogdana","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.07.016_b0005","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s11864-023-01114-y","article-title":"Antibody drug conjugates in bladder cancer: current milestones and future perspectives","volume":"24","author":"Alameddine","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.euf.2025.07.016_b0010","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.07.016_b0015","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-sacituzumab-govitecan-advanced-urothelial-cancer."},{"key":"10.1016\/j.euf.2025.07.016_b0020","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.euf.2025.07.016_b0025","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3892\/ol.2023.14114","article-title":"Immunohistochemical expression of TROP\u20112 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer","volume":"26","author":"Abbas","year":"2023","journal-title":"Oncol Lett"},{"key":"10.1016\/j.euf.2025.07.016_b0030","unstructured":"UroToday. AUA 2020: Phase 3 results of vicinium in BCG-unresponsive non-muscle invasive bladder cancer. https:\/\/www.urotoday.com\/conference-highlights\/aua-2020\/aua-2020-bladder-cancer\/122653-aua-2020-phase-3-results-of-vicinium-in-bcg-unresponsive-non-muscle-invasive-bladder-cancer.html."},{"key":"10.1016\/j.euf.2025.07.016_b0035","unstructured":"UroToday. ASCO 2023: EV-104: a first-in-human trial of intravesical enfortumab vedotin, an antibody-drug conjugate, in patients with NMIBC: interim results of a phase 1 study. https:\/\/www.urotoday.com\/conference-highlights\/asco-2023\/asco-2023-bladder-cancer\/144836-asco-2023-ev-104-a-first-in-human-trial-of-intravesical-enfortumab-vedotin-an-antibody-drug-conjugate-in-patients-with-nmibc-interim-results-of-a-phase-1-study.html."},{"key":"10.1016\/j.euf.2025.07.016_b0040","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.07.016_b0045","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discov"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925002226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925002226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:55:58Z","timestamp":1770144958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456925002226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2405456925002226"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.07.016","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Future of Novel Antibody-drug Conjugates in Localized Urothelial Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}